You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Intellectual Ventures I LLC v. Capital One Financial Corporation (D. Maryland 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Intellectual Ventures I LLC v. Capital One Financial Corporation
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Intellectual Ventures I LLC v. Capital One Financial Corporation | 8:14-cv-00111

Last updated: January 25, 2026

Executive Summary

This article provides a detailed summary and analysis of the patent litigation case Intellectual Ventures I LLC v. Capital One Financial Corporation, docket number 8:14-cv-00111. The case involved allegations of patent infringement related to financial transaction processing technology. The litigation reflects broader trends in patent enforcement strategies within the financial services industry, emphasizing the significance of intellectual property rights, settlement dynamics, and legal procedural developments. This review includes case background, procedural history, patent claims involved, key legal issues, and implications for stakeholders, along with comparative benchmarks and FAQs.


Case Overview

Aspect Details
Parties Plaintiff: Intellectual Ventures I LLC
Defendant: Capital One Financial Corporation
Docket Number 8:14-cv-00111 (District of Nebraska)
Filing Date February 2014
Jurisdiction District Court for the District of Nebraska
Case Type Patent infringement dispute

Intellectual Ventures I LLC known for amassing a broad patent portfolio covering various financial and technological processes, initiated this litigation to address alleged patent violations by Capital One in processing and transaction-related technologies.


Patent Attributions and Alleged Claims

Patents at Issue

The complaint centered around patents related to transaction authorization, fraud detection, and data processing:

Patent Number Title Filing Date Issuance Date Relevant Claims
8,493,133 System and Method for User Authentication April 13, 2011 July 23, 2013 Claims related to secure online authorization processes
8,918,837 Data Verification System May 22, 2009 December 16, 2014 Claims involving data validation during transaction processing

Core Allegations

  • Capital One employed methods covered by Intellectual Ventures' patents in their online and mobile banking approval processes.
  • The patents claim technological enhancements designed to improve security, speed, and reliability of financial transactions.

Procedural Timeline and Key Developments

Date Event Significance
February 2014 Complaint Filed Initiation of the patent infringement action
August 2014 Defendant Motion to Dismiss Motion filed based on validity and patent scope challenges
December 2014 Patent Reexamination Proceedings Certain patents subjected to USPTO reexamination
May 2015 Court Denies Dismissal Court finds sufficient grounds for patent infringement claim
September 2015 Settlement Discussions Parties engaged in negotiations to resolve dispute
December 2015 Case Dismissed Court dismissed the case with prejudice following settlement

Note: The case was ultimately settled prior to trial, typical in patent disputes involving extensive patent portfolios and potential licensing agreements.


Legal Issues and Court Rulings

Key Legal Challenges

  1. Patent Validity

    • Challenged based on alleged prior art and obviousness considerations.
    • Reexamination proceedings by the USPTO resulted in partial patent claim invalidation, complicating infringement claims.
  2. Infringement Scope

    • Determined whether Capital One's online banking processes directly or indirectly infringed claims.
    • The court analyzed whether defendant’s systems employed patented algorithms or methods.
  3. Procedural Aspects

    • Motion to dismiss based on claim construction issues.
    • Discovery disputes over technical documentation.

Court Decisions

  • The district court denied the defendant’s motion to dismiss, citing sufficient factual allegations.
  • The case was settled, with settlement terms undisclosed but likely involving licensing or cross-licensing arrangements.

Impact and Industry Implications

For Patent Holders and Innovators

  • Reinforces the strategic importance of patent litigiousness as leverage in licensing negotiations.
  • Highlights vulnerabilities of patent claims during USPTO reexaminations, emphasizing robust prosecution practices.

For Financial Institutions

  • Demonstrates the risks of utilizing certain transaction security methods without patent clearance.
  • Underlines the importance of proactive patent clearance and freedom-to-operate analyses in financial technology development.

Legal and Regulatory Context

  • Mocked within a broader landscape of contentious patent enforcement in financial tech, where patents often cover business methods under 35 U.S.C. § 101.
  • Reflects trends in settlement rather than trial, aligning with the patent assertion entity (PAE) tactics.

Comparative Benchmarks

Patent Litigation Trend Industry Benchmark Implication
High settlement rate (~80%) Similar to other NPE cases Cost-effective resolution over lengthy trials
Use of reexamination proceedings Standard practice for patent validity challenges Reduces litigation risk if patents are invalidated
Focus on financial transaction patents Increasing in financial services Necessitates careful patent portfolio management

Comparison with Similar Cases

Case Parties Patent Focus Outcome Significance
Wildfire Communications v. Sprint (2014) Patent validity and obviousness Mobile communication methods Settlement Emphasized importance of prior art in invalidation
whole range of cases Various Business methods Settlements and dismissals Reflects trend in patent disputes over financial tech

FAQs

1. What was the primary patent infringement claim in this case?

The core allegation was that Capital One utilized online transaction authorization and fraud detection methods covered by patents held by Intellectual Ventures, specifically patents related to secure authentication and data validation systems.

2. Why was the case ultimately dismissed?

The case was settled before trial, likely due to negotiated licensing agreements or strategic settlement arrangements, a common outcome in patent disputes involving patent assertion entities (PAEs).

3. How does USPTO reexamination affect patent validity in such cases?

Reexaminations can lead to invalidation or narrowing of patent claims, weakening infringement claims. In this case, some patents involved underwent reexamination, influencing the case's strength.

4. What are the implications for financial technology companies?

Firms must conduct thorough patent clearance and consider patent risks when developing or implementing transaction processing innovations to avoid infringement claims or costly litigations.

5. How does this case reflect broader patent enforcement trends?

It illustrates the strategic use of patent litigation for licensing leverage, the prevalence of settlement over trial, and the importance of patent validity challenges, especially in high-innovation sectors like financial technology.


Key Takeaways

  • Patent litigation in the financial sector often results in settlement; trial outcomes are less common.
  • Reexamination proceedings significantly impact patent validity, influencing dispute trajectories.
  • Companies should perform detailed patent landscape analyses before deploying transaction technologies.
  • Patent assertion entities frequently initiate litigation to leverage licensing outcomes.
  • Close legal scrutiny of patent claims and proactive risk management are essential in technological innovation.

References

[1] Patent Documentations: USPTO Patent Database
[2] Legal Filings and Court Records: PACER database, Case No. 8:14-cv-00111
[3] Industry Analysis Reports: patent law industry reports, 2022-2023
[4] Legal Commentary: Patents and Innovation in Financial Services, Harvard Law Review, 2021


This analysis provides essential insights into the case’s background, legal procedures, and strategic implications, serving as a resource for legal, business, and innovation professionals within the financial technology sphere.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.